Takeda

This study tested a dengue vaccine (TDV) in 187 healthy Japanese volunteers aged 4 to 60. Participants received two shots three months apart, and researchers checked how well the vaccine triggered an immune response against all four types of dengue virus. The goal is to see if th…

This study tested Takeda's dengue vaccine in 480 healthy people aged 4 to 60 in India. Participants received two doses of either the vaccine or a placebo three months apart. The main goals were to check for side effects and measure the body's immune response against all four type…

This study tested a new dengue vaccine (TDV) in over 20,000 healthy children aged 4 to 16. The goal was to see if two doses could prevent dengue fever caused by any of the four dengue virus types. Results help determine how well the vaccine works and its safety.

This study tested a new dengue vaccine in 30 healthy adults, some with prior dengue exposure and some without. The goal was to see how well the vaccine triggers the immune system to fight all four types of dengue virus. Researchers measured antibody levels over 12 months to check…

This study tested a new drug called TAK-079 when added to standard treatments for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The main goal was to find a safe dose and check for side effects. Fifty participants took part, and the results h…

This early-phase study tested a new drug (TAK-676) combined with pembrolizumab after radiation therapy in 34 adults with lung, triple-negative breast, or head/neck cancers that had stopped responding to standard treatments. The main goals were to check safety, side effects, and f…

This study tested a medicine called vedolizumab in 121 children with moderate to severe ulcerative colitis, a condition causing gut inflammation and pain. The goal was to see if the drug could bring about remission—meaning symptoms improve and the gut looks healthy on camera. Par…

This study looked at the safety of the drug Cabometyx in 263 Japanese people with a type of liver cancer called hepatocellular carcinoma. Participants took the drug as part of their normal care, and doctors watched for side effects over 12 months. The main goal was to see how oft…

This study tested a new drug combination (A+AVD) against the standard treatment (ABVD) for people with advanced Hodgkin lymphoma who had not been treated before. Over 1,300 participants were randomly assigned to one of the two treatments. The goal was to see which combination wor…

This study tested a drug called brentuximab vedotin in 50 adults with a rare type of lymphoma that had come back or not responded to prior chemotherapy. The goal was to see how many patients had their tumors shrink or disappear. Results showed the drug can effectively control the…

This study followed 48 people with hereditary angioedema (HAE) types I and II who were treated with lanadelumab through a Polish national drug program. Researchers tracked how many patients remained free of swelling attacks over 24 months, how many attacks required rescue medicat…

This study looked at how safe and effective VPRIV is for people with Gaucher disease in Japan. It included 63 patients who were either new to treatment or switching from another drug. Researchers tracked side effects and changes in blood health to see how well the medicine worked…

This study looked at the long-term safety of the drug vedolizumab in 59 children (ages 2-17) with ulcerative colitis or Crohn's disease. The main goal was to track any side effects that occurred during treatment. The study found that vedolizumab was generally safe for long-term u…

This study tested a new medicine called TAK-101 in 102 adults with celiac disease who already follow a gluten-free diet. The goal was to see if TAK-101 could reduce immune reactions and symptoms if they accidentally eat gluten. Participants received two doses of TAK-101 or a plac…

This study tested three different starting doses (15 mg, 30 mg, and 45 mg daily) of the drug ponatinib in 283 adults with chronic-phase chronic myeloid leukemia that had stopped responding to other treatments. The main goal was to see how well each dose reduced the level of leuke…

This study tested the drug brentuximab vedotin in 10 Chinese adults with a rare type of skin lymphoma called CD30-positive cutaneous T-cell lymphoma. The goal was to see if the drug could shrink or clear the cancer and to check for long-term side effects. Participants received th…

This study looked at the long-term safety and effectiveness of the drug vedolizumab (Entyvio) in over 1,100 people with moderate to severe ulcerative colitis who had not responded well to other treatments. Researchers tracked side effects and how well the drug controlled the dise…

This study tested whether adding pevonedistat to the standard drug azacitidine helps people with certain blood cancers live longer without their disease getting worse. It included 454 adults with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or low-blast…

This study tested a new medicine called TAK-881 in 65 people with primary immunodeficiency diseases (PIDD), which make it hard for the body to fight infections. The goal was to see how well the body processes TAK-881 compared to an existing treatment (HYQVIA) and to check its saf…

This study tested a drug called TAK-625 in 7 Japanese people with Alagille Syndrome, a rare liver condition. The goal was to see if the drug could improve symptoms like itching and lower bile acid levels. Participants took the drug for up to 34 months and had regular clinic visit…

This study tested a new drug called TAK-981 combined with pembrolizumab in 161 people with advanced or metastatic solid tumors that could not be cured. The main goals were to check safety and see if the combination could shrink tumors. Participants received treatment in 21-day cy…

This study looked at whether the drug vedolizumab can help adults with moderate to severe Crohn's disease achieve complete remission—meaning no symptoms, normal blood and stool tests, and healed bowel walls seen on ultrasound. 72 participants were treated with vedolizumab as part…

This study looked at the long-term safety of a drug called TAK-771 in 15 Japanese patients with primary immunodeficiency disease (PID), a condition where the immune system is weak. Participants who completed an earlier study received TAK-771 injections for up to 3 years. The main…

This study tested whether adding a drug called pevonedistat to the standard two-drug therapy (venetoclax and azacitidine) helps adults newly diagnosed with acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 164 participants received either t…

This study looked at 688 people with ulcerative colitis or Crohn's disease who received Vedolizumab (Kynteles) as part of their normal care in South Korea. The main goal was to track side effects and see how many patients felt better after treatment. Vedolizumab helps control inf…

This early-stage study tested a drug called mezagitamab in 17 people with IgA nephropathy, a kidney disease. The main goal was to check for side effects and see how the body processes the drug. Participants received weekly injections for 8 weeks, then every two weeks for 16 weeks…

This study tested a new drug called TAK-676, alone or with pembrolizumab, in 248 adults with advanced solid tumors that had no standard treatment options. The main goal was to find safe doses and check for side effects. The study did not aim to cure the cancer, but to control the…

This study tested two drugs, brigatinib and alectinib, in 248 people with a specific type of advanced lung cancer (ALK-positive NSCLC) that had worsened after a previous treatment. The goal was to see which drug better stopped tumor growth or shrank tumors. Participants took one …

This study tested a drug called leuprorelin in 80 children with central precocious puberty, a condition where puberty starts too early. The treatment is an injection given every 12 weeks for 6 months. The goal was to see if it could suppress puberty hormones and slow down physica…

This study tested a drug called TAK-755 in 29 adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare condition causing dangerous blood clots. The goal was to see if TAK-755, along with standard immune-suppressing drugs, could help patients recover without …

This study looked at side effects and how well azilsartan controls blood pressure in children aged 6 to 15 with high blood pressure. Five children took the drug once daily for up to 12 months. Doctors monitored for any unwanted effects and measured blood pressure changes.

This study looked at 115 Chinese people with hereditary angioedema (HAE) to see how well two approved medicines work in real life. One medicine, lanadelumab, is used to prevent attacks, and the other, icatibant, is used to stop attacks once they start. Researchers checked medical…

This study tested whether the drug TAK-625 could reduce severe itching and control bile acids in children with a rare, inherited liver disease called PFIC. Five Japanese children received the drug for up to 34 months, with regular clinic visits to monitor their symptoms and safet…

This study aimed to find better ways to detect Fabry disease early by analyzing hospital records from the past 10 years. Researchers used natural language processing, a type of computer analysis, to create a ranking algorithm that identifies patients most likely to have the disea…

This study tested whether an experimental drug called TAK-063 can reduce symptoms of schizophrenia during a sudden worsening (acute exacerbation). 164 adults with schizophrenia took either TAK-063 or a placebo daily for 6 weeks. The main goal was to see if the drug improved score…

This study tested a new medication called TAK-279 in 693 adults with moderate-to-severe plaque psoriasis. Participants received either TAK-279, an approved drug (apremilast), or a placebo for up to 61 weeks. The main goal was to see if TAK-279 could clear or nearly clear skin pla…

This early-stage study tested an experimental drug called TAK-063 in 77 people—some with stable schizophrenia and some healthy Japanese volunteers. The main goal was to see if the drug is safe and tolerable when taken daily for a week. Researchers monitored side effects, lab test…

This study tested an experimental drug called TAK-861 in 105 people with narcolepsy type 1, a condition that causes severe daytime sleepiness and sudden muscle weakness (cataplexy). The goal was to see if the drug could help people stay awake during the day and reduce the number …

This study looked at the safety and effectiveness of Firazyr (icatibant) for treating sudden swelling attacks in children (ages 2-17) with hereditary angioedema (HAE). Researchers tracked side effects and how quickly symptoms improved after the injection. The study involved 32 ch…

This study tested an experimental pill called TAK-279 in over 1,100 adults with moderate-to-severe plaque psoriasis. The goal was to see if it could clear or nearly clear skin plaques better than a placebo or an existing medication. Participants took TAK-279, an approved drug (ap…

This study looked at how the body handles a single injection of fazirsiran in people with mild, moderate, or severe liver problems compared to those with healthy livers. A total of 34 participants received one shot and were followed for 6 months. The goal was to understand drug l…

This study looked at whether a single dose of TAK-063 could prevent brain activity changes and psychotic-like symptoms caused by ketamine in 27 healthy adult men. Participants received TAK-063, a placebo, or ketamine in different sessions, and brain scans measured the drug's effe…

This study looked at nearly 24,000 older adults (65+) with ulcerative colitis or Crohn's disease to compare infection risks from three types of advanced treatments: ENTYVIO, TNF-alpha inhibitors, and ustekinumab. Researchers used existing Medicare claims data from 2016 to 2025 to…

This study looked at how common undiagnosed ADHD is in adults who already have another psychiatric condition. Researchers checked 224 adults to see if they had ADHD without knowing it and tracked their quality of life. The goal was to raise awareness and help prevent missed diagn…

This study looked back at medical records of 34 adults with von Willebrand disease (VWD) in the UK who received vonicog alfa (a lab-made clotting protein) to treat bleeding or prevent bleeding during surgery. The goal was to see how the drug was used in routine care and how well …

This study followed 646 people with complex fistulas caused by Crohn's disease or other conditions to see how well standard surgeries work in real-world clinics. Researchers tracked whether fistulas closed and if complications occurred, but did not provide any new treatment. The …

This study looked back at medical records of 330 kidney transplant patients in the UK to learn more about cytomegalovirus (CMV) infections that are hard to treat. The goal was to count how often these infections happen, what treatments are used, and how well they work. No new tre…

This study followed 354 people with ovarian cancer who were taking niraparib (Zedula) capsules daily as part of their normal care. The main goal was to watch for side effects like low blood cell counts, high blood pressure, and other serious issues over one year. Researchers did …

This early-phase study tested the safety and how the body processes TAK-123 in 10 healthy Japanese men aged 20 to 45. Participants received a single intravenous dose, and researchers measured drug levels and side effects. The study was completed and provides basic safety data, bu…

This completed Phase 1 trial studied how the body absorbs and clears two different subcutaneous immunoglobulin therapies, TAK-881 and HyQvia, in 30 healthy adults aged 18-50. Participants received a single injection and were monitored for 85 days. The goal was to compare the phar…

This study tested how well healthy adults tolerate a new medicine called TAK-881, given as an injection under the skin. 64 healthy volunteers aged 18-50 received one or more doses to check for side effects and how the body processes the drug. The goal was to see if the injection …

This study followed 165 people with inflammatory bowel disease (IBD) in Poland who were already taking or starting vedolizumab. Researchers simply observed whether patients chose intravenous (IV) or subcutaneous (SC) treatment, and how long they stayed on it. No new treatments or…

This study looked back at the medical records of 1,477 children diagnosed with central precocious puberty (early puberty) in China. The goal was to see how many received treatment and how well it worked. No new treatments were tested—the researchers simply collected information f…

This study tested a new drug called TAK-004 in 121 healthy adults to see if it is safe and how the body handles it. Participants received either TAK-004 or a placebo as an injection under the skin, and some got one dose while others got multiple doses. The goal was to learn about…

This study observed 92 adults with inflammatory bowel disease (Crohn's or ulcerative colitis) in Switzerland who were taking vedolizumab either as an IV infusion or a shot under the skin. Researchers tracked which route patients chose and why, and how long they stayed on treatmen…

This study followed 482 people with multiple myeloma in China who were already taking or about to start the drug Ninlaro as part of their normal care. The goal was to collect information on side effects and how the drug is used in everyday practice, not to test a new treatment. N…